Maxim Group Releases a Buy Rating on Brainstorm Cell Therapeutics (BCLI)

In a report released yesterday, Jason McCarthy from Maxim Group assigned a Buy rating to Brainstorm Cell Therapeutics (BCLIResearch Report), with a price target of $20.00. The company’s shares closed last Wednesday at $9.78.

According to TipRanks.com, McCarthy is a 5-star analyst with an average return of 22.4% and a 47.0% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Appili Therapeutics Inc Class A, SELLAS Life Sciences Group, and Lineage Cell Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Brainstorm Cell Therapeutics with a $20.00 average price target.

See today’s analyst top recommended stocks >>

Based on Brainstorm Cell Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $4.49 million. In comparison, last year the company had a GAAP net loss of $5.63 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Brainstorm Cell Therapeutics, Inc. operates as a biotechnology company, which develops and commercializes adult stem cell therapeutic products. It focuses on utilizing the patients own bone marrow stem cells to generate neuron-like cells that may provide an effective treatment initially for amyotrophic lateral sclerosis, Parkinson’s disease, multiple sclerosis and spinal cord injury. The company was founded on September 22, 2000 and is headquartered in New York, NJ.